1 |
Kurahashi S, Sano T, Natsume S, Senda Y, Yamaura H, Inaba Y, Shimizu Y. Surgical treatment after hepatic arterial infusion chemotherapy for hepatocellular carcinoma extending into the right atrium. Surg Case Rep 2015;1:47. [PMID: 26366344 DOI: 10.1186/s40792-015-0047-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
2 |
Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, Nakanishi K, Shimamura T, Todo S, Taketomi A. Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium. World J Surg Oncol. 2013;11:259. [PMID: 24093164 DOI: 10.1186/1477-7819-11-259] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 5.6] [Reference Citation Analysis]
|
3 |
Zhao H, Zhao Y, Guo Y, Huang Y, Lin S, Xue C, Xu F, Zhang Y, Zhao L, Hu Z, Zhang L. Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. Onco Targets Ther 2013;6:811-8. [PMID: 23861589 DOI: 10.2147/OTT.S46498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
4 |
Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, Kerbel RS. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 2010;12:928-40. [PMID: 21076618 DOI: 10.1593/neo.10804] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
|